. home.aspx

NEWS

home.aspx
   


Owkin’s machine learning tech to inform mesothelioma trials

October 09, 2019 / Richard Staines

A mesothelioma prognostic model from medical machine learning firm Owkin has been showcased in the journal Nature, and is being used to help further drug research into the often fatal disease. The paper, entitled “Deep learning-based classification of mesothelioma improves prediction of patient outcomes” describes Owkin’s technology called MesoNet, which has been trained using images from nearly 3,000 mesothelioma patients. Owkin used data from MESOBANK, a dataset containing images from several French institutions, and results were validated by experts in pathology at the renowned French Cancer Institute, Centre Leon Berard. As well as giving a prognosis, Owkin was able to use its deep learning technology to highlight regions of interest in the image associated with prognosis prediction. This has led to identification that helps explain different subtypes of the disease, the company said. Using insights from MesoNet, Owkin is working with pharma companies on selecting...